Protecting You, Your Family and Your Employees

Panelists and Context:

• The discussion features Alex Gorski (Johnson & Johnson Chairman & CEO), Dr. Mark McClellan (former FDA Commissioner), and Dr. Susan David (Harvard psychologist), addressing the intersection of the pandemic, racial justice, and business resilience.
• The conversation specifically targets small business owners and leaders navigating simultaneous crises in public health, economic stability, and social equity.

Emotional Agility and Organizational Resilience (Susan David):

• David asserts that business resilience is impossible without individual employee resilience, requiring the shift from rigid, siloed thinking to "emotional agility."
• Key Skills for Crisis:
  • Validate difficult emotions (anger, grief, anxiety) as normal biological adaptations to threat rather than targets for avoidance.
  • Treat negative emotions as signposts for core values (e.g., anger signaling a need for equity; loneliness signaling a need for connection).
  • Leaders must create a "pause" between stimulus and response to allow for intentional choice rather than autopilot operation.
• Actionable Shifts for Leaders:
  • Small business owners should audit systemic injustices in hiring, pay, and culture that conflict with their stated values.
  • Leadership should move from providing all answers to asking strategic questions about vision and team well-being.
  • Organizations must integrate "hearts and minds" with strategy to ensure meaningful execution.

Johnson & Johnson's Crisis Response (Alex Gorski):

• Employee Safety and Operations:
  • J&J has 130,000 employees; approximately 30,000 to 40,000 remain on-site in factories and labs to maintain medicine and instrument supply chains.
  • Immediate measures included closing facilities for remote work and providing support for employees managing family stressors (e.g., homeschooling).
• Strategic Pivot:
  • The company redirected resources to leverage its 10-year investment in viral vector technology to develop a COVID-19 vaccine.
  • J&J has announced a "not-for-profit" pricing model to ensure global affordability and access to the vaccine.
• Industry Collaboration:
  • Gorski highlights a shift from inter-company competition to a unified industry response against the virus, accelerating innovation across protein, RNA, and DNA platforms.
  • He warns that without secure public health systems, national security and economic stability are unattainable.

Vaccine Development Timeline and Strategy:

• Current Status:
  • The lead candidate utilizes a carrier virus (modified common cold virus) to introduce the coronavirus spike protein, triggering neutralizing antibodies.
  • Clinical trials in humans are scheduled to begin in the latter weeks of July.
  • The platform has previously been tested in over 65,000 patients (including in the Democratic Republic of Congo) with positive safety and efficacy data.
• Scale and Risk:
  • J&J can manufacture hundreds of millions of doses quickly due to pre-existing capacity, though the compressed timeline (5–6 months vs. the standard 5–7 years) is described as a "Herculean task."
  • The vaccine will not be a standalone panacea; it will require continued use of therapeutics, medicines, and established protocols.
• Collaborative Partnerships:
  • Development is conducted in close coordination with the FDA, BARDA, CDC, NIH, and international agencies to maintain safety standards.

Reopening Framework (Dr. Mark McClellan):

• Four-Phase Reopening Prerequisites:
  • Healthcare systems must not be stressed; excess capacity must be maintained to handle potential surges.
  • Access to testing must be widespread and equitable; positive cases must lead to isolation rather than immediate business shutdowns.
  • Contact tracing programs must be established to manage localized outbreaks effectively.
• Guidance for Small Businesses:
  • Implement social distancing protocols and contactless service options to reduce transmission risks.
  • Establish clear communication policies requiring employees with symptoms to stay home and providing information on local free testing resources.
  • Deep cleaning protocols are required following positive cases, but full business closure is not automatically necessary.
• Future Healthcare Shifts:
  • McClellan anticipates permanent structural changes in medical research, including parallel clinical trial phases and secure supply chains.
  • Policy changes to Medicare and private insurance are expected to favor telemedicine and community-based care to support workforce health.
  • There is a critical need to address health disparities exposed by the pandemic, particularly regarding race and socioeconomic status.